当前位置：
X-MOL 学术
›
Ophthalmology
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
Ophthalmology ( IF 13.1 ) Pub Date : 2020-03-18 , DOI: 10.1016/j.ophtha.2020.03.014 Hakan Demirci 1 , Cem Ozgonul 1 , Ana Beatriz Diniz Grisolia 1 , Victor M Elner 1
中文翻译：
利妥昔单抗鼻内注射治疗低度结膜淋巴瘤。
更新日期：2020-03-19
Ophthalmology ( IF 13.1 ) Pub Date : 2020-03-18 , DOI: 10.1016/j.ophtha.2020.03.014 Hakan Demirci 1 , Cem Ozgonul 1 , Ana Beatriz Diniz Grisolia 1 , Victor M Elner 1
Affiliation
Intralesional rituximab for low-grade conjunctival lymphoma provided complete response in 11(73%) eyes and partial response in 4(27%) eyes after 37-month(range,6-84) mean follow-up. Side effects were periocular swelling in 1 and allergic reaction in 2 patients.
中文翻译：
利妥昔单抗鼻内注射治疗低度结膜淋巴瘤。
平均随访37个月（6-84）后，低度结膜淋巴瘤的腹腔内利妥昔单抗提供了11例（73％）的完全缓解和4例（27％）的部分缓解。副作用为1眼眼红肿和2例过敏反应。
京公网安备 11010802027423号